|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081579 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-05 15:20:37 |
|
注册时间: Date of Registration: |
2024-03-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
组学联用技术在类风湿关节炎患者早期诊断和治疗中的应用价值 |
|
Public title: |
The value of combined omics technique in the early diagnosis and treatment of rheumatoid arthritis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
组学联用技术在类风湿关节炎患者早期诊断和治疗中的应用价值 |
|
Scientific title: |
The value of combined omics technique in the early diagnosis and treatment of rheumatoid arthritis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
卢伟锋 |
研究负责人: |
解丹丹 |
|
Applicant: |
luweifeng |
Study leader: |
xiedandan |
|
申请注册联系人电话: Applicant telephone: |
+86 13976610741 |
研究负责人电话:
Study leader's |
+86 13707572197 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
345101204@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
254862958@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
海南省海口市龙华区龙华路31号海南医学院第一附属医院 |
研究负责人通讯地址: |
海南省海口市龙华区31号 |
|
Applicant address: |
No. 31 Hainan Medical College Road, Longhua District, Haikou City, Hainan Province first affiliated |
Study leader's address: |
kejiaoke200707@163.com |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
海南医学院第一附属医院 |
||
|
Applicant's institution: |
First Affiliated Hospital of the Hainan Medical College |
||
|
研究负责人所在单位: |
海南医学院第一附属医院 |
||
|
Affiliation of the Leader: |
Hainan Medical College First Affiliated Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-KYL-056 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海南医学院第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Affiliated Hospital of Hainan Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-07 00:00:00 | ||
|
伦理委员会联系人: |
林萍 |
||
|
Contact Name of the ethic committee: |
Lin Ping |
||
|
伦理委员会联系地址: |
海南省海口市龙华区31号 |
||
|
Contact Address of the ethic committee: |
kejiaoke200707@163.com |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 898 66735891 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hyfylunli@163.com |
|
研究实施负责(组长)单位: |
海南医学院第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hainan Medical College First Affiliated Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省海口市龙华区31号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
kejiaoke200707@163.com |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
NA |
||||||||||||||||||||||
|
研究疾病: |
类风湿关节炎 |
||||||||||||||||||||||
|
Target disease: |
Rheumatoid arthritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
采用蛋白组学联合代谢组学技术对类风湿关节炎患者进行有效生物标志物和治疗靶点筛选 |
||||||||||||||||||||||
|
Objectives of Study: |
Proteomics combined with metabonomics was used to screen effective biomarkers and therapeutic targets in patients with rheumatoid arthritis |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.参照《类风湿关节炎诊疗规范》诊断类风湿关节炎; |
||||||||||||||||||||||
|
Inclusion criteria |
1.According to“Rheumatoid arthritis diagnosis and treatment norms” diagnosis of rheumatoid arthritis; |
||||||||||||||||||||||
|
排除标准: |
1.合并有严重的心血管、肝脏、肺部等疾病者;; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.patients with severe cardiovascular, liver and lung diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-01 00:00:00至 To 2026-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-11 00:00:00 至 To 2026-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Do not share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |